Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Tirzepatide improves cardiometabolic health in obesity.
Última actualización 11 de julio de 2026
Key finding
Mean BMI reductions were greater in those who improved BMI category (SURMOUNT-1: -8.90 kg/m²).
Tirzepatide treatment significantly improved cardiometabolic risk factors in adults with obesity or overweight.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
Tirzepatide treatment significantly improved cardiometabolic risk factors in adults with obesity or overweight.
Clinical relevance
The findings highlight the potential of tirzepatide as an effective treatment option for managing obesity and its associated health risks. By improving key cardiometabolic factors, tirzepatide may help reduce the incidence of conditions such as diabetes and cardiovascular disease, ultimately enhancing patient outcomes and quality of life.
Keep in mind
Effectiveness data remained unclear for some outcomes. Study design may limit generalizability to broader populations. Sample size and demographic diversity were not specified.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Naveed S, Clare JL, Reshmi S, et al. Tirzepatide treatment improves cardiometabolic risk factors in adults with obesity or overweight. American Journal of Preventive Cardiology. 2026;26:101454. doi:10.1016/j.ajpc.2026.101454
Efectos Principales
Mean BMI reductions of -8.90 kg/m² and -10.47 kg/m² were observed in participants treated with tirzepatide.
Significant decreases in body weight were noted in participants receiving tirzepatide.
Waist circumference and fasting insulin levels decreased significantly in the tirzepatide group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and BMI, Body weight, Diastolic blood pressure, and 6 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- BMI
- Body weight
- Diastolic blood pressure
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
9
Evidence pairs
9
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
5
Related topics
9
Evidence pairs
601
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 9 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Seguir evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Fasting Glucose
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 84
- Strong
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 8 studies
Add to Evidence TrackerDiastolic blood pressure
Tirzepatide → Diastolic blood pressure
Tirzepatide → Diastolic blood pressure
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Tirzepatide → Fasting Plasma Glucose (FPG)
Tirzepatide → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- ImpactScore™
- 75
- Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 85
- Strong
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 9 studies
Add to Evidence TrackerLongitudinal changes in cardiometabolic risk factors
Tirzepatide → Longitudinal changes in cardiometabolic risk factors
Tirzepatide → Longitudinal changes in cardiometabolic risk factors
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 83
- Positive
- EvidenceScore™
- 77
- Strong
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Tirzepatide treatment resulted in significant reductions in body weight and waist circumference.
- Fasting insulin and glucose levels decreased significantly with tirzepatide.
- Improvements in blood pressure and lipid profiles were observed in participants.
A quién se aplica
- Adults aged 18 and older with obesity or overweight.
- Individuals seeking pharmacological interventions for weight management.
Tener en Cuenta
- Results may not be applicable to populations outside the study's demographic.
- Long-term effects and safety of tirzepatide require further investigation.
- The study did not provide p-values for some outcomes, limiting statistical interpretation.
Entre Líneas
- Effectiveness data remained unclear for some outcomes.
- Study design may limit generalizability to broader populations.
- Sample size and demographic diversity were not specified.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceGLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 85
- Strong
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 9 studies
View evidenceMedications
Detailed evidenceGLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- 84
- Strong
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 8 studies
View evidenceMedications
Detailed evidenceGLP-1 Receptor Agonists → Blood Pressure
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
9 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
9 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
8 studies
outcome_hubMeasures Body Weight as a key outcome.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
2 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
9 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
8 results
All studies on Tirzepatide
Intervention: Tirzepatide
9 results
All studies measuring HbA1c
Outcome: HbA1c
9 results
All studies measuring Body weight
Outcome: Body weight
8 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 84.4 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.6 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control in early-onset type 2 diabetesDietary supplements may lower diabetes risk in prediabetesHRS-7535 improves glycemic control in adults with type 2 diabetesMediterranean ketogenic eating matched VLCKD for weight loss over 3 months
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.